2021
Prevalence and risk factors of cognitive impairment in children with sickle cell disease in Egypt
Youssry I, ElGhamrawy M, Seif H, Balsamo L, Pashankar F, Mahrous M, Salama N. Prevalence and risk factors of cognitive impairment in children with sickle cell disease in Egypt. International Journal Of Hematology 2021, 115: 399-405. PMID: 34792734, DOI: 10.1007/s12185-021-03260-1.Peer-Reviewed Original ResearchConceptsSickle cell diseaseHigh lactate dehydrogenaseCell diseaseCognitive impairmentRisk factorsLactate dehydrogenaseCairo University Children's HospitalOlder ageSickle cell disease patientsUniversity Children's HospitalPossible risk factorsMagnetic resonance angiographyMagnetic resonance imagingHydroxyurea therapyTranscranial DopplerChildren's HospitalDisease patientsUnivariate analysisEarly initiationPatientsResonance angiographyImpaired cognitionResonance imagingIntelligence quotient (IQ) testDisease
2018
Ovarian Yolk Sac Tumors; Does Age Matter?
Conter C, Xia C, Gershenson D, Hurteau J, Covens A, Pashankar F, Krailo M, Billmire D, Patte C, Fresneau B, Shaikh F, Stoneham S, Nicholson J, Murray M, Frazier AL. Ovarian Yolk Sac Tumors; Does Age Matter? International Journal Of Gynecological Cancer 2018, 28: 77-84. PMID: 29194189, DOI: 10.1097/igc.0000000000001149.Peer-Reviewed Original ResearchConceptsOvarian yolk sac tumorEvent-free survivalYolk sac tumorOverall survivalSac tumorClinical trialsOvarian germ cell tumorsPreoperative alpha-fetoprotein levelAge cut pointStage IV diseaseAdverse prognostic factorPlatinum-based chemotherapyAlpha-fetoprotein levelsCut pointsGerm cell tumorsPediatric clinical trialsRisk of eventsOptimal cut pointJoint pediatricChemosensitive tumorsChemotherapeutic regimenPrognostic impactPrognostic factorsAdult trialsGynecologic oncologists
2015
Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International Collaborative
Pashankar F, Hale JP, Dang H, Krailo M, Brady WE, Rodriguez-Galindo C, Nicholson JC, Murray MJ, Bilmire DF, Stoneham S, Arul GS, Olson TA, Stark D, Shaikh F, Amatruda JF, Covens A, Gershenson DM, Frazier AL. Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International Collaborative. Cancer 2015, 122: 230-237. PMID: 26485622, PMCID: PMC5134834, DOI: 10.1002/cncr.29732.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAnalysis of VarianceBiopsy, NeedleChemotherapy, AdjuvantChildCohort StudiesDisease-Free SurvivalFemaleHumansImmunohistochemistryMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingOvarian NeoplasmsRegistriesRisk AssessmentSurvival AnalysisTeratomaYoung AdultConceptsImmature teratomaAdult clinical trialsGrade 1 diseaseOvarian immature teratomaRole of chemotherapyPostoperative chemotherapyPediatric patientsAdult trialsPediatric trialsPooled analysisClinical trialsStage IAdult womenTrialsChemotherapyCollaborative data setPatientsSurgeryTeratomaDiseaseWomen
2014
Revised Risk Classification for Pediatric Extracranial Germ Cell Tumors Based on 25 Years of Clinical Trial Data From the United Kingdom and United States
Frazier AL, Hale JP, Rodriguez-Galindo C, Dang H, Olson T, Murray MJ, Amatruda JF, Thornton C, Arul GS, Billmire D, Shaikh F, Pashankar F, Stoneham S, Krailo M, Nicholson JC. Revised Risk Classification for Pediatric Extracranial Germ Cell Tumors Based on 25 Years of Clinical Trial Data From the United Kingdom and United States. Journal Of Clinical Oncology 2014, 33: 195-201. PMID: 25452439, PMCID: PMC4279239, DOI: 10.1200/jco.2014.58.3369.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAge FactorsAlpha-FetoproteinsBiomarkers, TumorChildChild, PreschoolClinical Trials as TopicDisease-Free SurvivalEndodermal Sinus TumorEvidence-Based MedicineFemaleHumansMaleModels, StatisticalNeoplasm StagingNeoplasms, Germ Cell and EmbryonalPredictive Value of TestsPrognosisRetrospective StudiesRisk AssessmentRisk FactorsUnited KingdomUnited StatesConceptsGerm cell tumorsYolk sac tumorPediatric germ cell tumorsClinical trial dataAlpha-fetoproteinTumor siteOncology GroupCell tumorsMalignant pediatric germ cell tumorsPediatric extracranial germ cell tumorLong-term disease-free survivalEvidence-based risk stratificationExtracranial germ cell tumorsTrial dataPure yolk sac tumorPoor-risk groupStage IV diseaseDisease-free survivalPercentage of patientsChildren's Oncology GroupElevated alpha-fetoproteinPlatinum-based therapyClinical trial organizationsParametric cure modelsLeukemia group
2013
Weight Status of Children With Sickle Cell Disease
Chawla A, Sprinz PG, Welch J, Heeney M, Usmani N, Pashankar F, Kavanagh P. Weight Status of Children With Sickle Cell Disease. Pediatrics 2013, 131: e1168-e1173. PMID: 23460681, DOI: 10.1542/peds.2012-2225.Peer-Reviewed Original ResearchConceptsSickle cell diseaseBaseline Hb levelsHb levelsBMI percentileWeight statusCell diseaseHigher baseline Hb levelsSCD-related complicationsRetrospective chart reviewObesity-related conditionsOverweight/obesityRecent clinic visitYears of ageCalendar year 2007Select comorbiditiesChart reviewClinic visitsDL increaseElevated BMIHemoglobin levelsObese statusSickle genotypeUnderweight individualsHb SSDemographic information
2012
Management of Thyroid Carcinoma in Children and Young Adults
Rapkin L, Pashankar FD. Management of Thyroid Carcinoma in Children and Young Adults. Journal Of Pediatric Hematology/Oncology 2012, 34: s39-s46. PMID: 22525405, DOI: 10.1097/mph.0b013e31824e37a6.Peer-Reviewed Original ResearchConceptsMedullary thyroid cancerThyroid cancerRadioactive iodineCancers of childhoodSuppression of thyroidPediatric carcinomasAdjuvant benefitNew medicationsSuspicious lesionsThyroid carcinomaBeneficial treatmentCancerAdolescent treatmentPatientsYoung adultsAdult dataWDTCSurgeryCarcinomaTreatmentChildhoodLow thresholdLarge groupMedicationsVandetanib